Argenx提出雄心勃勃的2025年计划,旨在扩大药物覆盖面和推进多种临床研究。 Argenx outlines ambitious 2025 plans, aiming to expand drug reach and advance multiple clinical studies.

Argenx是一家免疫学公司,报告2024年全球销售额达22亿美元,并概述了2025年的优先事项。 Argenx, an immunology company, reports $2.2 billion in global sales for 2024 and outlines 2025 priorities. 计划包括扩大VYVGART的全球覆盖范围,并推出预填式注射器版本。 Plans include expanding VYVGART's global reach and launching a pre-filled syringe version. 该公司将为其输油管进行10项注册和10项概念证明研究,包括efgartigimod和empasiprubart。 The company will conduct 10 registrational and 10 proof-of-concept studies for its pipeline, including efgartigimod and empasiprubart. Argenx的目标是到2030年治疗50 000名病人,将5名候选人推进到第三阶段。 Argenx aims to treat 50,000 patients and advance five candidates into Phase 3 by 2030.